Lowest Price Guaranteed From USD 2,199
The global anti CD19 therapeutics market is likely to be worth USD 12.0 billion by 2030, growing at a CAGR of 41.0 % during the forecast period. The human immune system is comprised of a number of different types of specialized molecules and cells that are involved in complex interactions and activities to facilitate an immune response. Immunotherapies exploit the body's innate potential to specifically target a particular molecular antigen and mount an efficient immune response against the cells bearing the diseased signature. Currently, four major types of immunotherapies (classified by product class) targeting the CD19 antigen are under development, namely engineered antibodies, bispecific antibodies (bsAbs), antibody drug conjugates (ADCs) and CAR-T cell therapies. CD19 antigen, an important biomarker has emerged as a promising therapeutic target for a number of disease indications, specifically hematological malignancies (leukemias and lymphomas). The antigen is expressed both on normal cells and malignant B cells as well as follicular dendritic cells. Upon initial discovery, the CD19 antigen was dubbed as the B4 antigen on human B cells.
The pioneer anti CD19 drug to hit the US and the EU markets was BLINCYTO® (blinatumomab), a bsAb. Different technologies have catered to the development of anti CD19 drug candidates. Several researchers and therapy developers are actively involved in developing therapeutics targeting the CD19 antigen for the treatment of B cell malignancies and various autoimmune disorders. With several advantages such as high therapeutic performance and favorable clinical outcomes, the promising pipeline of anti CD19 drug candidates is expected to result in a multi-billion dollar market by 2030.
Several recent developments have taken place in the field of CD19 therapeutics market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The ‘CD19 Therapeutics Market, 2016-2030’ market report provides a comprehensive analysis of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the CD19 therapeutics market. The recent approval of BLINCYTO®, a CD19 targeting bsAb, and emergence of CAR-T therapies has provided a significant boost to this market that has actively evolved in the past few years.
The pipeline comprises of products across four major classes of drugs, namely, engineered antibodies, bsAbs, ADCs and CAR-T therapies. The major focus of these novel molecules is hematological cancers, specifically B cell malignancies, with CAR-T therapies leading the table. Post initial research in CAR-T therapies, many non-industry players have entered into collaborations with industry stakeholders to fund the clinical and commercial development of these products. Some late stage products that have emerged out of such collaborations include KTE-C19, CTL019, JCAR015 and JCAR017.
One of the key objectives of the market report is to review and quantify the opportunities laid by the innovative CD19 targeted programs of both small and big pharma firms. Amongst other elements, the market research report elaborates upon the following key areas:
The key objective of CD19 therapeutics market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for CD19 therapeutics market during the forecast period. The research, analysis and insights presented in this market report include potential sales of various marketed and late stage (phase II and phase II/III) anti CD19 products based on our understanding of the likely future development of individual therapeutics. The opinions and insights, presented in this market research report, were influenced by discussions that we conducted with experts in this area. These included senior representatives at Kite Pharma, MorphoSys and Theravectys.
Owing to niche nature of the market, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry evolution. All actual figures have been sourced and analyzed from publicly available information and discussions with industry experts. The figures mentioned in this market report are in USD, unless otherwise specified.